Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Sellas Life Sciences (SLS) has a market cap of $80.235 million USD. According to our data, Sellas Life Sciences is ranked No.7852 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $80.24 M |
9.62%
|
| Dec 31, 2024 | $73.20 M |
-1.89%
|
| Dec 29, 2023 | $74.60 M |
-55.08%
|
| Dec 30, 2022 | $0.17 B |
-57.32%
|
| Dec 31, 2021 | $0.39 B |
-4.82%
|
| Dec 31, 2020 | $0.41 B |
35.12%
|
| Dec 31, 2019 | $0.30 B |
-93.01%
|
| Dec 31, 2018 | $4.33 B |
-84.23%
|
| Dec 29, 2017 | $27.45 B |
-86.60%
|
| Dec 30, 2016 | $204.81 B |
-93.40%
|
| Dec 31, 2015 | $3.104 T |
-2.65%
|
| Dec 31, 2014 | $3.188 T |
-69.56%
|
| Dec 31, 2013 | $10.473 T |
224.18%
|
| Dec 31, 2012 | $3.231 T |
225.53%
|
| Dec 30, 2011 | $992.39 B |
-81.78%
|
| Dec 31, 2010 | $5.448 T |
-43.67%
|
| Dec 31, 2009 | $9.670 T |
-20.35%
|
| Dec 31, 2008 | $12.141 T |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
 Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
 Karyopharm Therapeutics
KPTI
|
$84.09 M |
0.000 M
|
USA
|
 MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
 Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
 Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
 Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
 Agenus
AGEN
|
$86.42 M |
0.000 M
|
USA
|
 Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
 Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
 bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
 Gritstone bio
GRTS
|
$3.80 M |
2.350 M
|
USA
|
| Market Cap | = | SLS Stock Price | * | SLS Shares Outstanding |
| = | $1.14 | * | 70.38 M | |
| = | $80.24 M |